 At each study visit, infants will receive a full skin examination to evaluate for signs of atopic dermatitis AD. The Infant Dermatitis Quality of Life Index IDQOLI will be administered to parents at each study visit to screen for possible signs of AD such as infant irritability, skin rashes and hypersensitivity. If AD is present, the Scoring Atopic Dermatitis SCORAD grading system will be used to assess severity. Urine samples will be collected at each study visit to measure levels of fatty acid binding proteins FABPs and glutathione-S-transferase alpha-GST, which are non-invasive markers of gastrointestinal permeability that may indicate the presence of food allergies. Blood will be collected via finger or heel stick at weeks 6 and 52 for immune phenotyping including measuring inflammatory cytokines and food-specific IgEs. In addition, levels of serum fatty acid binding proteins FABPs and glutathione-S-transferase alpha-GST will be measured as markers of gastrointestinal permeability and potential food allergy. Parents will also complete surveys at each study visit to monitor the infants for potential adverse events associated with probiotic administration including feeding intolerance, fevers, or bowel irregularities including constipation and diarrhea. 